下颌下腺转位联合调强放疗减少头颈癌患者口干
仅1例出现3级唾液腺毒性;放疗后12个月无或轻度口干率为89%,唾液流率约为放疗前的75%。结论认为该联合方案可行,优化剂量约束后可能最大程度保护腮腺与下颌下腺,减少口干并改善生活质量。
要点
- 放疗后12个月无或轻度口干率89%,唾液流率约为放疗前75%
- 联合方案可行,优化剂量约束后可能进一步保护唾液腺功能
核心结论
- IMRT联合SMGT可行,配合改进的剂量约束可能最大程度保护腮腺与下颌下腺,减少口干并改善患者生活质量。
研究设计与样本
- 单中心、前瞻性II期可行性试验;头颈癌或原发不明伴颈部淋巴结转移患者接受原发手术加SMGT及术后螺旋断层放疗(60 Gy分30次)。
主要发现
- 仅1例患者出现3级唾液腺毒性。
- 放疗后12个月,无口干或仅轻度口干的比例为89%。
- 放疗后12个月唾液流率约为放疗前水平的75%。
临床怎么用
- 对需术后放疗的头颈癌患者,可考虑SMGT联合IMRT以保留唾液腺功能、减少口干并改善生活质量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Xerostomia is a debilitating side effect of radiotherapy for head and neck cancer. Combining surgical submandibular-gland transfer (SMGT) with intensity-modulated radiotherapy (IMRT) may provide greater protection of salivary function. METHODS: This was a single-institution, prospective phase II feasibility trial. Patients with head and neck cancer or unknown primary with neck node metastases received primary surgery with SMGT and postoperative radiotherapy with tomotherapy (60 Gy in 30 fractions). Toxicity and quality of life (QOL) were assessed before surgery, before RT, and after RT. RESULTS: Forty patients received SMGT and IMRT. Only 1 patient experienced grade 3 salivary gland toxicity. At 12 months post-RT, the rate of absent or only mild xerostomia was 89%, and salivary flow rates were approximately 75% of pre-RT levels. CONCLUSIONS: The combination of IMRT with SMGT is feasible and with improved dose constraints may maximally spare the parotid and submandibular glands, leading to decreased xerostomia and improved patient QOL.
引用
- Scrimger RA, Seikaly H, Vos LJ, et al. Combination of submandibular salivary gland transfer and intensity-modulated radiotherapy to reduce dryness of mouth (xerostomia) in patients with head and neck cancer. Head Neck. 2018. PMID: 30175876. doi:10.1002/hed.25339
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。